Larimar Therapeutics

LRMR

Market cap $332M

4.00 USD

+0.35

9.59%

At close Updated Dec 22, 4:00 PM EST

Pre-market

After hours

3.94

-0.06

1.5%

1 day

9.59%

5 days

3.09%

1 month

9.29%

3 months

-10.71%

6 months

65.29%

Year to date

-0.25%

1 year

1.01%

5 years

-81.46%

10 years

-95.02%

About: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Employees: 65

Healthcare Biotechnology